SCHEMBL723055

SCHEMBL723055

CSCCCCC(=O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.42
MAPK1 P28482 1/20 0.40
SLC13A3 Q8WWT9 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
OR51E2 Q9H255 1/20 0.40
CES2 O00748 5/20 0.39
CES1 P23141 5/20 0.39
HAO1 Q9UJM8 1/20 0.38
RNPEP Q9H4A4 1/20 0.35
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20855304 0.98 FOLH1 (0.41) FOLH1MAPK1SLC13A3EGLN1OR51E2
SCHEMBL31429799 0.98 FOLH1 (0.41) FOLH1MAPK1SLC13A3EGLN1OR51E2
SCHEMBL6300371 0.98 FOLH1 (0.41) FOLH1MAPK1SLC13A3EGLN1OR51E2
SCHEMBL720525 0.93 FOLH1 (0.44) FOLH1MAPK1SLC13A3EGLN1OR51E2
SCHEMBL9936985 0.88 TSHR (0.52) FOLH1MAPK1SLC13A3EGLN1OR51E2
SCHEMBL126896 0.82
SCHEMBL14777048 0.80 OR51E2 (0.43) FOLH1MAPK1SLC13A3EGLN1OR51E2
SCHEMBL14776551 0.80 OR51E2 (0.43) FOLH1MAPK1SLC13A3EGLN1OR51E2
SCHEMBL2554930 0.80
SCHEMBL17323034 0.78 TSHR (0.60) FOLH1OR51E2ALDH1A1LMNAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257630-B1 BIOSYNTHETIC ENGINEERING OF GLUCOSINOLATES UNIV COPENHAGEN (DK) 2016-09-28 EP disclosed
US-9096863-B2 Biosynthetic engineering of glucosinolates University of Denmark (DK) 2015-08-04 US disclosed
EP-2550251-B1 PROCESS FOR PRODUCING SULFUR-CONTAINING AMINO ACID OR SALT THEREOF SUMITOMO CHEMICAL CO (JP) 2015-04-29 EP disclosed
US-8779190-B2 Process for producing sulfur-containing amino acid or salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-07-15 US disclosed
EP-2609077-A1 PROCESS FOR PREPARING SULFUR-CONTAINING 2-KETOCARBOXYLATE COMPOUND Sumitomo Chemical Company Limited (JP) 2013-07-03 EP disclosed
US-20130137897-A1 PROCESS FOR PREPARING SULFUR-CONTAINING 2-KETOCARBOXYLATE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-05-30 US disclosed
US-20130137896-A1 PROCESS FOR PREPARING SULFUR-CONTAINING 2-KETOCARBOXYLATE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-05-30 US disclosed
EP-2550251-A1 PROCESS FOR PRODUCING SULFUR-CONTAINING AMINO ACID OR SALT THEREOF Sumitomo Chemical Company, Limited (JP) 2013-01-30 EP disclosed
US-20130012737-A1 PROCESS FOR PRODUCING SULFUR-CONTAINING AMINO ACID OR SALT THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-01-10 US disclosed
WO-2012026620-A1 PROCESS FOR PREPARING SULFUR-CONTAINING 2-KETOCARBOXYLATE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-03-01 WO disclosed
WO-2011118849-A1 PROCESS FOR PRODUCING SULFUR-CONTAINING AMINO ACID OR SALT THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-29 WO disclosed
US-20110016582-A1 Biosynthetic Engineering of Glucosinolates UNIVERSITY OF COPENHAGEN (DK) 2011-01-20 US disclosed
EP-2257630-A2 BIOSYNTHETIC ENGINEERING OF GLUCOSINOLATES University of Copenhagen (DK) 2010-12-08 EP disclosed
WO-2009106985-A2 BIOSYNTHETIC ENGINEERING OF GLUCOSINOLATES UNIVERSITY OF COPENHAGEN (DK) 2009-09-03 WO disclosed
US-6977297-B1 Methods and means for modification of glucosinolates in plants PLANT BIOSCIENCE LIMITED (GB) 2005-12-20 US disclosed
EP-1032691-A1 METHODS AND MEANS FOR MODIFICATION OF GLUCOSINOLATES IN PLANTS Plant Bioscience Limited (GB) 2000-09-06 EP disclosed
WO-1999027120-A1 METHODS AND MEANS FOR MODIFICATION OF GLUCOSINOLATES IN PLANTS PLANT BIOSCIENCE LIMITED (GB) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137896-A1 PROCESS FOR PREPARING SULFUR-CONTAINING 2-KETOCARBOXYLATE COMPOUND HPD, STS, HACL2 FOLH1 1683/4885MAPK1 3231/4885SLC13A3 2215/4885
US-20130137897-A1 PROCESS FOR PREPARING SULFUR-CONTAINING 2-KETOCARBOXYLATE COMPOUND HPD, STS, HAO2 FOLH1 2035/4885MAPK1 3482/4885SLC13A3 1888/4885
US-20130012737-A1 PROCESS FOR PRODUCING SULFUR-CONTAINING AMINO ACID OR SALT THEREOF CBS, ASS1, TST FOLH1 3385/4885MAPK1 335/4885SLC13A3 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.